Could a single infusion of 'Peacekeeper' cells let kidney transplant patients ditch most of their meds?

NCT ID NCT06552169

Recruiting now Disease control Sponsor: Singulera Therapeutics Inc. Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial tests whether a single infusion of a patient's own regulatory T cells (TRK-001) can prevent the immune system from attacking a new kidney. 34 living-donor kidney transplant recipients will either receive standard anti-rejection drugs alone or those drugs plus the cell infusion. The goal is to see if the cell therapy allows patients to safely reduce to just one anti-rejection medication a year after transplant, while avoiding rejection and other complications.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: regulatory T cells (TRK-001) plus standard immunosuppression drugs
What this could lead to: If successful, this could allow kidney transplant recipients to safely reduce their lifelong anti-rejection medications to just one drug, lowering side effects and improving quality of life.
What could go wrong: This is a small, early-phase trial (34 people) testing safety and feasibility. The cell therapy may not work as hoped, and reducing immunosuppression could increase rejection risk. Long-term benefits are uncertain.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for END-STAGE RENAL DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic kidney disease end stage renal failure transplant rejection prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

KIDNEY TRANSPLANTATION

Contacts and locations

Locations

Chang Gung Medical Foundation Hospital
RECRUITING

Taoyuan, 333, Taiwan
Mayo Clinic in Arizona
RECRUITING

Phoenix, Arizona, 85054, United States
Mayo Clinic in Minnesota
RECRUITING

Rochester, Minnesota, 55905, United States
National Cheng Kung University Hospital
NOT_YET_RECRUITING

Tainan, 704, Taiwan
National Taiwan University Hospital
RECRUITING

Taipei, 100229, Taiwan
Northwestern Memorial Hospital
RECRUITING

Chicago, Illinois, 60611, United States
Taichung Veterans General Hospital
RECRUITING

Taichung, 407219, Taiwan

More trials for these conditions

Other studies related to the condition(s) this trial covers.